OPEN ACCESS Freely available online

Journal of Nanomedicine & Biotherapeutic Discovery

Commentary

Enhancing Bioavailability through Nanoscale Drug Delivery

Sarah Huang*

Department of Microbiology, Bangladesh Agricultural University, Mymensingh, Bangladesh

DESCRIPTION

Bioavailability, the proportion of a drug that enters the circulation and can have an active effect, is a critical factor in the effectiveness of pharmaceuticals. Despite significant advancements in drug development, many therapeutics suffer from poor bioavailability, limiting their efficacy. Nanoscale drug delivery systems offer a promising solution to this challenge, enhancing the bioavailability of various drugs and improving therapeutic outcomes.

Understanding bioavailability

Bioavailability is influenced by multiple factors, including the drug's solubility, stability, and permeability. Oral drugs, for example, must survive the acidic environment of the stomach, be absorbed through the intestinal lining, and evade first-pass metabolism in the liver. Drugs administered *via* other routes, such as intravenous or transdermal, face their own unique barriers.

Enhancing bioavailability means ensuring a higher percentage of the administered dose reaches systemic circulation and exerts its intended effect. Traditional methods to improve bioavailability include modifying the drug's chemical structure, using co-solvents, or employing prodrugs. However, these approaches can have limitations and may not be feasible for all drugs.

The role of nanoscale drug delivery systems

Nanoscale drug delivery systems, including nanoparticles, liposomes, micelles, and dendrimers, provide innovative solutions to enhance bioavailability. These systems can improve solubility, protect drugs from degradation, facilitate targeted delivery, and promote controlled release.

Improving solubility and dissolution rate: Poor water solubility is a common issue that limits the bioavailability of many drugs. Nanoscale systems increase the surface area to volume ratio, enhancing the dissolution rate of poorly soluble drugs. Nanoparticles, for example, can be engineered to encapsulate hydrophobic drugs, improving their dispersion in biological fluids.

Protecting drugs from degradation: Many drugs degrade before reaching their target site. Encapsulation within nanoscale carriers can shield drugs from harsh environmental conditions, such as the acidic pH of the stomach or enzymatic degradation in the gastrointestinal tract. Liposomes, which are vesicles composed of lipid bilayers, can protect sensitive drugs until they reach their site of action.

Enhancing permeability and absorption: Nanoscale carriers can facilitate the transport of drugs across biological barriers. For oral drugs, nanoparticles can enhance absorption through the intestinal epithelium. They can also improve transdermal delivery by penetrating the stratum corneum, the outermost layer of the skin, which is a major barrier to drug absorption.

Targeted delivery: One of the most significant advantages of nanoscale drug delivery systems is their ability to target specific tissues or cells. By modifying the surface of nanoparticles with ligands or antibodies, drugs can be directed to specific sites, such as tumor cells or inflamed tissues, reducing off-target effects and increasing therapeutic efficacy.

Controlled release: Nanoscale systems can be designed to release their payloads in a controlled manner, ensuring a steady supply of the drug over time. This can help maintain therapeutic drug levels in the bloodstream, reducing the frequency of dosing and improving patient compliance.

Types of nanoscale drug delivery systems

Nanoparticles: Nanoparticles, typically ranging from 1 to 100 nanometers in size, can be made from various materials including polymers, lipids, and metals. They can encapsulate drugs, enhancing their solubility and protecting them from degradation. Polymeric nanoparticles, for example, can be engineered to release drugs in a controlled manner, improving bioavailability and therapeutic outcomes.

Liposomes: Liposomes are spherical vesicles with one or more phospholipid bilayers, which can encapsulate both hydrophilic and hydrophobic drugs. They are biocompatible and can fuse with cell membranes, facilitating drug delivery. Liposomal

Correspondence to: Sarah Huang, Department of Microbiology, Bangladesh Agricultural University, Mymensingh, Bangladesh, E-mail: Haungsarah@gmail.com

Received: 29-Apr-2024, Manuscript No. JNBD-24-31584; **Editor assigned:** 02-May-2024, PreQC No. JNBD-24-31584 (PQ); **Reviewed:** 16-May-2024, QC No. JNBD-24-31584; **Revised:** 23-May-2024, Manuscript No. JNBD-24-31584 (R); **Published:** 30-May-2024, DOI: 10.4172/2155-983X.24.14.253

Citation: Huang S (2024) Enhancing Bioavailability through Nanoscale Drug Delivery. J Nanomedicine Biotherapeutic Discov. 14:253.

formulations have been used to enhance the bioavailability of various drugs, including anticancer agents and vaccines.

Micelles: Micelles are self-assembling colloidal structures formed by amphiphilic molecules in aqueous environments. They have a hydrophobic core that can solubilize poorly soluble drugs and a hydrophilic shell that enhances stability and circulation time. Micelles can improve the bioavailability of hydrophobic drugs by increasing their solubility and protecting them from degradation.

Dendrimers: Dendrimers are highly branched, tree-like macromolecules with multiple functional groups on their surface. These functional groups can be modified to enhance drug solubility, targeting, and controlled release. Dendrimers have shown potential in improving the bioavailability of various drugs by facilitating their delivery and reducing toxicity.

Challenges and future perspectives

While nanoscale drug delivery systems offer significant advantages for enhancing bioavailability, there are challenges that need to be addressed.

Toxicity and biocompatibility: The long-term safety of nanoparticles and their potential toxicity need thorough evaluation. Ensuring that nanocarriers are biocompatible and do not induce adverse immune responses is important.

Scalability and manufacturing: The production of nanoscale drug delivery systems must be scalable and cost-effective. Standardizing manufacturing processes to ensure consistency and quality is a major challenge.

Regulatory hurdles: Regulatory approval for nanomedicines can be complex, as it requires comprehensive evaluation of their safety, efficacy, and potential risks. Regulatory agencies need to develop specific guidelines for nanoscale drug delivery systems.

Despite these challenges, the future of nanoscale drug delivery is promising. Advances in nanotechnology and materials science are likely to yield new and improved nanocarriers with enhanced capabilities. Personalized medicine, where nanoscale systems are tailored to individual patient needs, is an exciting frontier that could revolutionize healthcare.

CONCLUSION

Nanoscale drug delivery systems represent a significant advancement in the quest to enhance drug bioavailability. By improving solubility, protecting drugs from degradation, facilitating targeted delivery, and enabling controlled release, these systems offer solutions to many of the limitations of traditional drug delivery methods. As research and development in nanotechnology continue to progress, nanoscale drug delivery systems are poised to play an increasingly important role in modern medicine, improving therapeutic outcomes and patient quality of life.